MARKET OUTLOOK Extensive-stage SCLC is an incurable disease for which very few treatment options exist. Platinum-based chemotherapy was the standard of care for these patients until the approval…
Clarivate Epidemiology's coverage of small-cell lung cancer (SCLC) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Treatment of small-cell lung cancer (SCLC) has long been dominated by chemo(radio)therapy, but the standard of care for first-line extensive-stage SCLC recently changed, following the FDA’s…
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…
For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squibb’s Opdivo became the first immune…
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key renal cell carcinoma patient populations covering 171 countries and more than…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…